Atossa Therapeutics (ATOS) vs Lipocine (LPCN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lipocine (LPCN) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 53.2% versus a loss of 86.4%. Over five years, LPCN leads with a -92.3% price change compared with -95.3% for ATOS. Lipocine is the larger company by market cap ($16.4 million vs $15.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | LPCN |
|---|---|---|
| Share price | $1.60 | $1.48 |
| Market cap | $15.92M | $16.39M |
| 1-day change | -8.86% | -1.33% |
| YTD return | -81.98% | -81.57% |
| 1-year return | -86.37% | -53.16% |
| 5-year return | -95.34% | -92.30% |
| EPS (TTM) | $-3.92 | $-1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.98M |
| Revenue growth (YoY) | — | -82.35% |
| Net income (latest FY) | $-34.77M | $-9.63M |
| Operating margin | — | -524.69% |
| Net margin | — | -487.06% |
| 52-week high | $14.85 | $12.37 |
| 52-week low | $1.59 | $1.36 |
| Distance from 52-week high | -89.26% | -88.04% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1091.22% | +237.84% |
| Average volume | 68.00K | 1.84M |
| Shares outstanding | 9.98M | 11.07M |
| Employees | 16 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LPCN has outperformed ATOS by 33.2 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
ATOS vs LPCN FAQ
Which is bigger, Atossa Therapeutics or Lipocine?
Lipocine (LPCN) is larger, with a market capitalization of $16.39M compared with $15.92M for Atossa Therapeutics (ATOS).
Which stock has performed better over the past year, ATOS or LPCN?
LPCN returned -53.16% over the past 12 months, compared with -86.37% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and Lipocine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.